eyenovia-logo 3

Eyenovia Announces Conference Call and Webcast for Second Quarter 2019 Financial Results

News Release

Printer Friendly Version View printer-friendly version << Back
August 6, 2019 at 8:30 AM EDT

Eyenovia Announces Conference Call and Webcast for Second Quarter 2019 Financial Results

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results for the second quarter ended June 30, 2019 on Monday, August 12, 2019, after the market closes. Following the release, Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, and John Gandolfo, Chief Financial Officer, will host a conference call to review the financial results.

The conference call is scheduled to begin at 4:30 pm ET on Monday, August 12, 2019. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 6217226. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until August 19, 2019. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404-537-3406 (International) with confirmation code 6217226.

About Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. For more Information please visit www.eyenovia.com.

Company Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Investor Contact:
The Ruth Group
Tram Bui / Alexander Lobo
646-536-7035/7037
[email protected] / [email protected]

Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]

 

Eyenovia Logo 311 x 109.png

Source: Eyenovia, Inc.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

295 Madison Ave., Suite 2400, New York, NY 10017     +1 (917) 289-1117

[email protected]